Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human treated dentine matrix (hTDM) is a bioactive, acellular scaffold derived from human teeth, specifically processed to remove cellular components while preserving the structural integrity and biochemical cues of the dentine. The treatment process, often involving demineralization with agents like EDTA, exposes endogenous growth factors such as Bone Morphogenetic Protein-2 (BMP-2), Transforming Growth Factor-beta 1 (TGF-β1), and Fibroblast Growth Factor-2 (FGF-2) that are naturally sequestered within the hydroxyapatite matrix. These factors promote the recruitment, proliferation, and odontogenic differentiation of dental pulp stem cells (DPSCs). hTDM is primarily utilized in regenerative dentistry for applications such as dental pulp regeneration, apexogenesis, and as a bone graft substitute due to its excellent biocompatibility, osteoconductivity, and inductive properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human treated dentine matrix.